

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.397; Belimumab for treating active autoantibody-positive systemic lupus erythematosus

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline UK (Belimumab (Benlysta)) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Action on Pain • Anticoagulation UK • Arthritis & Musculoskeletal Alliance • Arthritis Action • Black Health Agency • British Sjögren's Syndrome Association • Contact • Changing Faces • Disability Rights UK • Equalities National Council • Genetic Alliance UK • Jnetics • Kidney Care UK • Leonard Cheshire Disability • Let's Face It • Lupus UK • Lupus Trust • Muslim Council of Britain • National Children's Bureau • National Kidney Federation • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Pain UK • Psoriasis and Psoriatic Arthritis Alliance • Psoriasis Association • Psoriasis Help Organisation • Raynaud's & Scleroderma Association 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Baxter Healthcare (cyclophosphamide) • Pfizer (cyclophosphamide) • Roche Pharmaceuticals (rituximab) • Celltrion (rituximab biosimilar) • Sandoz GmbH (rituximab biosimilar) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • British Epidermo-Epidemiology Society • British Society for Immunology

<ul style="list-style-type: none"> • South Asian Health Foundation • Specialised Healthcare Alliance • Thrombosis UK • Versus Arthritis <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses & Counsellors • Association of Renal Industries • Association of Renal Technologists • British Association for Surgery of the Knee • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Orthopaedic Foot and Ankle Society • British Pain Society • British Renal Society • British Skin Foundation • British Society for Allergy and Clinical Immunology • British Society for Children's Orthopaedic Surgery • British Society for Gene and Cell therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Human Genetics • British Society for Paediatric and Adolescent Rheumatology • British Society for Rheumatology • British Society of Haemostasis and Thrombosis • British Society of Rehabilitation Medicine • British Thoracic Society • Clinical Leaders of Thrombosis • Physiotherapy Pain Association • Primary Care Dermatology Society • Primary Care Rheumatology Society • Renal Association • Rheumatoid Arthritis Surgical Society 	<ul style="list-style-type: none"> • Centre of Evidence-Based Dermatology, University of Nottingham • Chronic Pain Policy Coalition • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Musculoskeletal Group • Cochrane Peripheral Vascular Disease Group • Cochrane Skin Group • Genomics England • Kidney Research UK • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Skin Research Centre • Skin Treatment and Research Trust • Thrombosis Research Institute <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Aberdeen HTA Group <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Guidelines Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	--

<ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Vascular Technology • Society of Vascular Nurses • The Vascular Society of Great Britain and Ireland • UK Clinical Pharmacy Association • UK Genetic Testing Network • UK National Screening Committee • UK Primary Immunodeficiency Network • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bexley CCG • NHS West London CCG • Welsh Government 	
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.